TY - JOUR
T1 - PKD2-Related Autosomal Dominant Polycystic Kidney Disease
T2 - Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis
AU - Cornec-Le Gall, Emilie
AU - Audrézet, Marie Pierre
AU - Renaudineau, Eric
AU - Hourmant, Maryvonne
AU - Charasse, Christophe
AU - Michez, Eric
AU - Frouget, Thierry
AU - Vigneau, Cécile
AU - Dantal, Jacques
AU - Siohan, Pascale
AU - Longuet, Hélène
AU - Gatault, Philippe
AU - Ecotière, Laure
AU - Bridoux, Frank
AU - Mandart, Lise
AU - Hanrotel-Saliou, Catherine
AU - Stanescu, Corina
AU - Depraetre, Pascale
AU - Gie, Sophie
AU - Massad, Michiel
AU - Kersalé, Aude
AU - Séret, Guillaume
AU - Augusto, Jean François
AU - Saliou, Philippe
AU - Maestri, Sandrine
AU - Chen, Jian Min
AU - Harris, Peter C.
AU - Férec, Claude
AU - Le Meur, Yannick
N1 - Funding Information:
Support: This study was conducted with the support of the National Plan for Clinical Research (PHRC regional 2010), Groupement Inter-Régional de Recherche Clinique et d’Innovation (GIRGI Grand-Ouest), the Société Française de Néphrologie , and the Institut National de la Santé et de la Recherche Médicale (INSERM). Dr Cornec-Le Gall is currently funded by an American Society of Nephrology Foundation Kidney Research Fellowship. The funders of this study did not have any role in the design or interpretation of the data.
Funding Information:
Support: This study was conducted with the support of the National Plan for Clinical Research (PHRC regional 2010), Groupement Inter-R?gional de Recherche Clinique et d'Innovation (GIRGI Grand-Ouest), the Soci?t? Fran?aise de N?phrologie, and the Institut National de la Sant? et de la Recherche M?dicale (INSERM). Dr Cornec-Le Gall is currently funded by an American Society of Nephrology Foundation Kidney Research Fellowship. The funders of this study did not have any role in the design or interpretation of the data.
Publisher Copyright:
© 2017 National Kidney Foundation, Inc.
PY - 2017/10
Y1 - 2017/10
N2 - Background PKD2-related autosomal dominant polycystic kidney disease (ADPKD) is widely acknowledged to be of milder severity than PKD1-related disease, but population-based studies depicting the exact burden of the disease are lacking. We aimed to revisit PKD2 prevalence, clinical presentation, mutation spectrum, and prognosis through the Genkyst cohort. Study Design Case series, January 2010 to March 2016. Settings & Participants Genkyst study participants are individuals older than 18 years from 22 nephrology centers from western France with a diagnosis of ADPKD based on Pei criteria or at least 10 bilateral kidney cysts in the absence of a familial history. Publicly available whole-exome sequencing data from the ExAC database were used to provide an estimate of the genetic prevalence of the disease. Outcomes Molecular analysis of PKD1 and PKD2 genes. Renal survival, age- and sex-adjusted estimated glomerular filtration rate. Results The Genkyst cohort included 293 patients with PKD2 mutations (203 pedigrees). PKD2 patients with a nephrology follow-up corresponded to 0.63 (95% CI, 0.54-0.72)/10,000 in Brittany, while PKD2 genetic prevalence was calculated at 1.64 (95% CI, 1.10-3.51)/10,000 inhabitants in the European population. Median age at diagnosis was 42 years. Flank pain was reported in 38.9%; macroscopic hematuria, in 31.1%; and cyst infections, in 15.3% of patients. At age 60 years, the cumulative probability of end-stage renal disease (ESRD) was 9.8% (95% CI, 5.2%-14.4%), whereas the probability of hypertension was 75.2% (95% CI, 68.5%-81.9%). Although there was no sex influence on renal survival, men had lower kidney function than women. Nontruncating mutations (n = 36) were associated with higher age-adjusted estimated glomerular filtration rates. Among the 18 patients with more severe outcomes (ESRD before age 60), 44% had associated conditions or nephropathies likely to account for the early progression to ESRD. Limitations Younger patients and patients presenting with milder forms of PKD2-related disease may not be diagnosed or referred to nephrology centers. Conclusions Patients with PKD2-related ADPKD typically present with mild disease. In case of accelerated degradation of kidney function, a concomitant nephropathy should be ruled out.
AB - Background PKD2-related autosomal dominant polycystic kidney disease (ADPKD) is widely acknowledged to be of milder severity than PKD1-related disease, but population-based studies depicting the exact burden of the disease are lacking. We aimed to revisit PKD2 prevalence, clinical presentation, mutation spectrum, and prognosis through the Genkyst cohort. Study Design Case series, January 2010 to March 2016. Settings & Participants Genkyst study participants are individuals older than 18 years from 22 nephrology centers from western France with a diagnosis of ADPKD based on Pei criteria or at least 10 bilateral kidney cysts in the absence of a familial history. Publicly available whole-exome sequencing data from the ExAC database were used to provide an estimate of the genetic prevalence of the disease. Outcomes Molecular analysis of PKD1 and PKD2 genes. Renal survival, age- and sex-adjusted estimated glomerular filtration rate. Results The Genkyst cohort included 293 patients with PKD2 mutations (203 pedigrees). PKD2 patients with a nephrology follow-up corresponded to 0.63 (95% CI, 0.54-0.72)/10,000 in Brittany, while PKD2 genetic prevalence was calculated at 1.64 (95% CI, 1.10-3.51)/10,000 inhabitants in the European population. Median age at diagnosis was 42 years. Flank pain was reported in 38.9%; macroscopic hematuria, in 31.1%; and cyst infections, in 15.3% of patients. At age 60 years, the cumulative probability of end-stage renal disease (ESRD) was 9.8% (95% CI, 5.2%-14.4%), whereas the probability of hypertension was 75.2% (95% CI, 68.5%-81.9%). Although there was no sex influence on renal survival, men had lower kidney function than women. Nontruncating mutations (n = 36) were associated with higher age-adjusted estimated glomerular filtration rates. Among the 18 patients with more severe outcomes (ESRD before age 60), 44% had associated conditions or nephropathies likely to account for the early progression to ESRD. Limitations Younger patients and patients presenting with milder forms of PKD2-related disease may not be diagnosed or referred to nephrology centers. Conclusions Patients with PKD2-related ADPKD typically present with mild disease. In case of accelerated degradation of kidney function, a concomitant nephropathy should be ruled out.
KW - Autosomal dominant polycystic kidney disease (ADPKD)
KW - PKD2
KW - case series
KW - disease progression
KW - disease severity
KW - end-stage renal disease (ESRD)
KW - genetic prevalence
KW - genetics
KW - kidney function
KW - mutation detection
KW - mutation spectrum
KW - prognosis
KW - renal survival
KW - sequencing
UR - http://www.scopus.com/inward/record.url?scp=85016019912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016019912&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.01.046
DO - 10.1053/j.ajkd.2017.01.046
M3 - Article
C2 - 28356211
AN - SCOPUS:85016019912
SN - 0272-6386
VL - 70
SP - 476
EP - 485
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 4
ER -